EP Patent

EP2364703A1 — Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for administration shortly after amiodarone discontinuation

Assigned to Sanofi SA · Expires 2011-09-14 · 15y expired

What this patent protects

The present invention concerns the use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention and/or treatment of patients with atrial fibrillation (AF) or atrial Flutter (AFL), shortly after discontinuation of …

USPTO Abstract

The present invention concerns the use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention and/or treatment of patients with atrial fibrillation (AF) or atrial Flutter (AFL), shortly after discontinuation of a previous treatment with amiodarone.

Drugs covered by this patent

Patent Metadata

Patent number
EP2364703A1
Jurisdiction
EP
Classification
—
Expires
2011-09-14
Drug substance claim
No
Drug product claim
No
Assignee
Sanofi SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.